Zhonglian Pharmaceutical

Shenzhen Zhonglian Pharmaceutical Co., Ltd. was founded in 1988 and is mainly engaged in the research and development, production, sales and after-sales service of endocrine system drugs. It is a wholly-owned subsidiary of Shenzhen Zhonglian Guangshen Pharmaceutical (Group) Joint-stock Co., Ltd. Since its establishment 30 years ago, Shenzhen Zhonglian Pharmaceutical Co., Ltd. has always adhered to the corporate spirit of "pragmatic, enterprising, excellence" and the business policy of "scientific, rigorous, standardized". In the endocrine field, in the direction of drugs for treating diabetes and thyroid diseases, it has created well-known brand drugs nationwide such as "Jiangtangjun Meidikang (Metformin Hydrochloride Tablets)", "Jiaheng (Levothyroxine Sodium Tablets)", and "Bujitai (Potassium Chloride Sustained-release Tablets)". It has been rated many times as a "Civilized Enterprise", "Contract-honoring and Credit-keeping Enterprise", "Trustworthy Enterprise in Labor Management", and "High-tech Enterprise" in Shenzhen, as well as an "Advanced Quality and Benefit-oriented Enterprise" in Guangdong Province. In July 2019, Jiangtangjun Meidikang successfully passed the generic drug consistency evaluation. Zhonglian Pharmaceutical obtained the dual certification of the new version of GMP for raw materials and preparations in 2015, and has first-class production equipment and workshops fully compliant with GMP standards. In order to achieve long-term development and better adapt to the requirements of the pharmaceutical industry, with the caring concern and strong support of the Shenzhen Municipal Government and the Pingshan District Committee and District Government, the Zhonglian Pharmaceutical factory project has settled in the Pingshan Biomedical Industry Park, gaining an opportunity for another take-off. After completion, the new factory will present a modern enterprise that complies with the latest domestic and international pharmaceutical GMP industry standards, and is designed and built with intelligent, environmentally friendly, efficient automation, and specialized R&D and production. The planned construction area of the new factory is more than 50,000 square meters, with a designed annual production capacity of 2.8 billion tablets (capsules) of oral solid chemical preparations. If you want to see a thousand miles farther, go up one more floor. While building the new factory, the enterprise is also vigorously advancing drug consistency evaluation and new drug research and development. Zhonglian Pharmaceutical will forge ahead and strive for excellence, contributing to the Pingshan Biomedical Park and the future health industry of Shenzhen.